Nuclera
Making biology accessible by providing researchers a desktop bioprinter capable to produce genes and proteins in one day.
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 9872 % | (45 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (179534 %) | (2961 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (286316 %) | (3498 %) | (20289 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Nuclera is a biotechnology company specializing in on-demand gene to protein synthesis, enabling scientists to create, build, and engineer biology directly in their own laboratories. The company serves researchers and scientists in the field of synthetic biology, providing high-quality genes and proteins with a focus on speed, flexibility, and accuracy. Nuclera operates in the synthetic biology market, leveraging a biologically inspired platform that allows for the rapid construction of genes, often within a day. The business model revolves around selling its proprietary technology and related services to laboratories and research institutions, generating revenue through the sale of its synthesis platform and consumables. By making gene and protein writing accessible and customizable, Nuclera aims to revolutionize the way biological research is conducted.
Keywords: gene synthesis, protein synthesis, synthetic biology, biotechnology, laboratory tools, research, high accuracy, customization, rapid construction, benchtop technology.